Chronic Coronary Syndrome, Chronic Coronary Total Occlusion, Coronary Arterial Disease (CAD), Stable Chronic Angina, NT-pro-BNP
Conditions
Keywords
NT-pro-BNP, Coronary Arterial Disease (CAD), Chronic Coronary Syndrome (CCS)
Brief summary
This study aim to investigate the association between plasma NT-proBNP levels and the presence, extent and severity of stenosis in patients with suspected coronary artery disease.
Detailed description
The investigators prospectively measured plasma NT-proBNP levels in consecutive patients referred to the center for elective diagnostic coronary angiography due to symptoms or signs of coronary artery disease over a two- year period. Patients with conditions known to elevate NT-proBNP levels, including heart failure, severe valvular disease, atrial fibrillation, severe chronic kidney disease (eGFR \< 30 mL/min), prior coronary artery bypass grafting, or age over 80 years, were excluded.
Interventions
DIAGNOSTIC_TESTBNP
Measurement of plasma NT-proBNP level.
Sponsors
IRCCS Ospedale San Raffaele
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient referred for elective coronary angiography due to suspected CAD. * NT-proBNP measurement during hospitalization
Exclusion criteria
* heart failure * severe valvular disease * atrial fibrillation * severe chronic kidney disease (eGFR \< 30 mL/min) * prior coronary artery bypass grafting * age over 80 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Association between plasma NT-proBNP levels and the presence, extension and severity of angiographic lesions in patients with suspected CAD. | Plasma NT-proBNP levels are quantified on the morning before coronary angiography. The CAD burden is independently evaluated by two experienced interventional cardiologists periprocedurally and immediately after the coronary angiography. | Plasma NT-proBNP levels are quantified on the morning before coronary angiography using a highly sensitive electrochemiluminescence immunoassay (ECLIA) method (NT-proBNP, Roche Diagnostics, Germany), employing the Roche Modular Analytics E170 immunoassay analyzer AL. The aim of this study is to explore the association between these levels and the presence (critical vs non-critical), location (prognostic vs non-prognostic), severity (\>70%, 70-99%, 100%) and extent of obstructive lesions detected in a contemporary cohort of patients undergoing coronary angiography for suspected CAD. Coronary angiograms are independently evaluated by two experienced interventional cardiologists (C.G. and C.G.) who are blinded to the NT-proBNP levels. |
Countries
Italy
Contacts
Primary ContactCarlo Gaspardone
Outcome results
None listed